Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Exp Brain Res ; 165(3): 362-74, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15968457

RESUMO

In Parkinson's disease (PD), the striatal dopamine depletion and the following overactivation of the indirect pathway of the basal ganglia leads to very early disinhibition of the subthalamic nucleus (STN) that may contribute to the progression of PD by glutamatergic overstimulation of the dopaminergic neurons in the substantia nigra. Adenosine A2A antagonism has been demonstrated to attenuate the overactivity of the striatopallidal pathway. To investigate whether neuroprotection exerted by the A2A antagonist 8-(3-chlorostyryl)caffeine (CSC) correlates with a diminution of the striatopallidal pathway activity, we have examined the changes in the mRNA encoding for enkephalin, dynorphin, and adenosine A2A receptors by in situ hybridization induced by subacute systemic pretreatment with CSC in rats with striatal 6-hydroxydopamine(6-OHDA) administration. Animals received CSC for 7 days until 30 min before 6-OHDA intrastriatal administration. Vehicle-treated group received a solution of dimethyl sulfoxide. CSC pretreatment partially attenuated the decrease in nigral tyrosine hydroxylase immunoreactivity induced by 6-OHDA, whereas no modification of the increase in preproenkephalin mRNA expression in the dorsolateral striatum was observed. The neuroprotective effect of the adenosine A2A antagonist CSC in striatal 6-OHDA-lesioned rats does not result from a normalization of the increase in striatal PPE mRNA expression in the DL striatum, suggesting that other different mechanisms may be involved.


Assuntos
Antagonistas do Receptor A2 de Adenosina , Cafeína/análogos & derivados , Neostriado/fisiologia , Fármacos Neuroprotetores , Doença de Parkinson Secundária/tratamento farmacológico , Animais , Cafeína/farmacologia , Contagem de Células , Dinorfinas/biossíntese , Encefalinas/biossíntese , Globo Pálido/fisiologia , Imuno-Histoquímica , Hibridização In Situ , Masculino , Microinjeções , Vias Neurais/fisiologia , Oxidopamina/administração & dosagem , Doença de Parkinson Secundária/induzido quimicamente , Precursores de Proteínas/biossíntese , RNA Mensageiro/biossíntese , Ratos , Ratos Sprague-Dawley , Receptor A2A de Adenosina/biossíntese , Comportamento Estereotipado/efeitos dos fármacos , Substância Negra/citologia , Simpatolíticos/administração & dosagem , Tirosina 3-Mono-Oxigenase/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA